Pasar al contenido principal

TERAPIA ANTITUMORAL MEDIANTE LA SECRECION ENDOGENA DE ANTICUEPOS BIESPECIFICOS CON CAPACIDAD DE REDIRIGIR CEULAS T

PI20/01030

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL 12 DE OCTUBRE
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL 12 DE OCTUBRE (i+12)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

  • Díez-Alonso, Laura
  • Falgàs, Aïda
  • Arroyo-Ródenas, Javier
  • Romencín, Paola A
  • Martínez, Alba
  • Gómez-Rosel, Marina
  • Blanco, Belén
  • Jiménez-Reinoso, Anaïs
  • Mayado, Andrea
  • Pérez-Pons, Alba
  • Aguilar-Sopeña, Óscar
  • Ramírez-Fernández, Ángel
  • Segura-Tudela, Alejandro
  • Perez-Amill, Lorena
  • Tapia-Galisteo, Antonio
  • Domínguez-Alonso, Carmen
  • Rubio-Pérez, Laura
  • Jara-Acevedo, Maria
  • Solé, Francesc
  • Hangiu, Oana
  • Almagro, Laura
  • Albitre, Ángela
  • Penela, Petronila
  • Sanz, Laura
  • Anguita, Eduardo
  • Valeri, Antonio
  • García-Ortiz, Almudena
  • Río, Paula
  • Juan, Manel
  • Martínez-López, Joaquín
  • Roda-Navarro, Pedro
  • Martin-Antonio, Beatriz
  • Orfao, Alberto
  • Menéndez, Pablo
  • Bueno, Clara
  • Álvarez-Vallina, Luis
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric antigen receptors (CARs) and systemically injected bispecific T cell engagers (TCEs), has shown remarkable clinical activity, and several products have received market approval. However, despite promising results, most patients eventually become refractory and relapse, highlighting the need for alternative strategies. Engineered T cells secreting TCE antibodies (STAb) represent a promising strategy that combines the advantages of adoptive cell therapies and bispecific antibodies. Here, we undertook a comprehensive preclinical study comparing the therapeutic potential of T cells either expressing second-generation anti-BCMA CARs (CAR-T) or secreting BCMAxCD3 TCEs (STAb-T) in a T cell–limiting experimental setting mimicking the conditions found in patients with relapsed/refractory multiple myeloma. STAb-T cells recruited T cell activity at extremely low effector-to-target ratios and were resistant to inhibition mediated by soluble BCMA released from the cell surface, resulting in enhanced cytotoxic responses and prevention of immune escape of multiple myeloma cells in vitro. These advantages led to robust expansion and persistence of STAb-T cells in vivo, generating long-lived memory BCMA-specific responses that could control multiple myeloma progression in xenograft models, outperforming traditional CAR-T cells. These promising preclinical results encourage clinical testing of the BCMA-STAb-T cell approach in relapsed/refractory multiple myeloma., Financial support for this work was obtained from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2020-115444GB-I00 to P.R.-N., PID2019-108160RB-I00 to P.M., PLE2021-0075 to C.B., and PID2020-117323RB-100 and PDC2021-121711-100 to L.Á.-V.), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (PI20/01030 to B.B., PI19/00132 to L.S., PI21-01834 to P.P., PI20/00822 to C.B., and DTS20/00089 to L.Á.-V.), partially supported by the ERDF; the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia) (RD21/0017/0030 to B.B. and J.M.-L. and RD21/0017/0029 to P.M.); the ISCIII-CIBERONC program (CB16/12/00400 to A.O.), the CRIS Cancer Foundation (FCRIS-2021-001 to J.M.-L. and FCRIS-2021-0090 to L.Á.-V.), the Spanish Association Against Cancer (AECC) (PRYGN234975MENE to P.M., PRYGN211192BUEN to C.B., and PROYE19084ALVA and PRYGN234844ALVA to L.Á.-V.); the Accelerator Award-Cancer Research UK/AIRC/AECC-INCAR (GEACC18001ORF to A.O.), the Fundación “La Caixa” (LCF/PR/HR19/52160011 to P.M. and HR21-00761 project IL7R_LungCan to L.Á.-V.), the European Research Council (ERC) (ERC-PoC-957466 to P.M.) and ERC under the EU’s Horizon Program (grant agreement 101100665 to P.M.), the Fundación de Investigación Biomédica 12 de Octubre (programa Investiga 2022-0082) to L.Á.-V.; the Fundación Ramón Areces to P.P. L.D.-A. was supported by a Rio Hortega fellowship from the Carlos III Health Institute (CM20/00004). A.F. was supported by a postdoctoral fellowship from the Spanish Ministry of Science and Innovation (FJC2021-046789-I). A. Mayado was supported by the CIBERONC (PRF-2869). A.P.-P. was supported by a grant from the Government of Castilla y León (Orden EDU/556/2019; Valladolid, Spain). M.G.-R. was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD-23732). O.A.-S. was supported by a PhD fellowship from the Complutense University of Madrid. C.D.-A. was supported by a PhD fellowship from the Spanish Ministry of Science and Innovation (PRE2018-083445). L.R.-P. was supported by a PhD fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck. O.H. was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2020/BMD-17668). A.V. is supported by Research Institute Hospital 12 de Octubre (imas12). A.G.-O. is supported by HIGEA 2019/0123 AIE project to J.M.-L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

  • Blanco, Belén
  • Ramírez-Fernández, Ángel
  • Bueno, Clara
  • Argemí-Muntadas, Lidia
  • Fuentes, Patricia
  • Aguilar-Sopeña, Óscar
  • Gutierrez-Agüera, Francisco
  • Zanetti, Samanta Romina
  • Tapia-Galisteo, Antonio
  • Díez-Alonso, Laura
  • Segura-Tudela, Alejandro
  • Castellà, Maria
  • Marzal, Berta
  • Betriu, Sergi
  • Harwood, Seandean L.
  • Compte, Marta
  • Lykkemark, Simon
  • Erce-Llamazares, Ainhoa
  • Rubio-Pérez, Laura
  • Jiménez-Reinoso, Anaïs
  • Domínguez-Alonso, Carmen
  • Neves, Maria
  • Morales, Pablo
  • Paz-Artal, Estela
  • Guedan, Sonia
  • Sanz, Laura
  • Toribio, María L.
  • Roda-Navarro, Pedro
  • Juan, Manel
  • Menéndez, Pablo
  • Álvarez-Vallina, Luis
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies., European Research Council (CoG-2014-646903, PoC-2018-811220) Spanish Ministry of Science and Innovation (PID2019-105623RB-I00, SAF2016-75656-P, RTC-2017-5944-1, SAF-2019-108160-R, SAF2017-89437-P, PID2020-117323RB-100, PDC2021-121711-100) Carlos III Health Institute (PI20/01030, PI20/00822, PI16/00357, PI19/00132, PICI14/122, PI13/676, PIE13/33, PI18/775, DTS20/00089) CatSalut, Fundació La Caixa (CP042702) Spanish Association Against Cancer (AECC CICPF18030TORI, AECC 19084) CRIS Cancer Foundation (FCRIS-IFI-2018, FCRIS-IFI-2020) Spanish Ministry of Science and Innovation under a Ramon y Cajal grant (RYC2018-024442-I) Comunidad Autónoma de Madrid (PEJD-2018- PRE/BMD-8314) ISCIII (CM20/00004) Spanish Ministry of Science and Innovation (PRE2018-083445) Portuguese Foundation for Science and Technology (SFRH/BD/136574/2018)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager

  • Gómez-Rosel, Marina
  • Rubio-Pérez, Laura
  • Zagorac, Ivana
  • Domínguez-Alonso, Carmen
  • Díez-Alonso, Laura
  • Hangiu, Oana
  • Navarro, Rocío
  • Torres-Ruiz, Raúl
  • Rodriguez-Perales, Sandra
  • Blanco, Francisco J.
  • Compte, Marta
  • Álvarez-Vallina, Luis
  • Blanco, Belén
22 páginas, 5 figuras, Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (Secretion of T cell-redirecting bispecific Antibodies)-T-cell immunotherapy represents a promising alternative by enabling both polyclonal T-cell recruitment and sustained bispecific antibody release. Here, we describe an evolution of STAb-T19 therapy, which has demonstrated superior outcomes to those of CAR-T-19 cells in preclinical models of B-ALL, on the basis of the simultaneous secretion of two bispecific antibodies: a CD19 × CD3 TCE and a PD-L1 × 4-1BB bsAb. The combined approach aims to increase the antitumor efficacy of STAb-T19 cells by blocking the PD-1/PD-L1 axis with conditional 4-1BB costimulation to ensure the long-term persistence of STAb-T cells. Preclinical data show that this combination improves cytotoxic activity and prolongs antileukemic efficacy compared with low-dose single STAb-T therapy. Our findings suggest that the integration of PD-L1 × 4-1BB bsAbs into STAb-T19 therapy may maximize efficacy, thereby opening a promising avenue to address resistance and relapse in B-ALL. Moreover, this approach may pave the way for the development of next-generation cell-based therapies for hematologic and solid malignancies., BB is funded by Fundación Científica de la Asociación Española Contra el Cáncer (INNOV211832BLAN), the Comunidad de Madrid (IND2022/BMD−23732) and the Instituto de Salud Carlos III (ISCIII) (PI20/01030, PI23/01256). LA-V is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021−121711-I00, CPP2022−009762, CPP2022−009765, CPP2023−010827), ISCIII (DTS20/ 00089, PMPTA22/00167), the Asociación Española contra el Cáncer (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS−2021−0090 and FCRIS−2023−0070), the Fundación ‘‘La Caixa’’ (HR21−00761 project IL7R_LungCan), the Comunidad de Madrid (P2022/BMD−7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). M.G.-R. is supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD−23732). FJB is funded by PID2023-152271NB-I00 from MCIN/AEI/10.13039/501100011033. We thank the Proteomics service at CIC bioGUNE and the Molecular Interactions service at CIB-CSIC for assisting with the mass spectrometry and SEC-MALS experiments. This study has adhered to ARRIVE guidelines, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

  • Blanco, Belén
  • Ramírez-Fernández, Ángel
  • Bueno, Clara|||0000-0003-1442-6216
  • Argemí-Muntadas, Lidia
  • Fuentes, Patricia
  • Aguilar-Sopeña, Óscar
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Tapia-Galisteo, Antonio
  • Díez-Alonso, Laura
  • Segura-Tudela, Alejandro
  • Castellà, Maria
  • Marzal, Berta
  • Betriu-Méndez, Sergi|||0000-0002-4199-1168
  • Harwood, Seandean L.
  • Compte, Marta
  • Lykkemark, Simon
  • Erce-Llamazares, Ainhoa
  • Rubio-Pérez, Laura
  • Jiménez-Reinoso, Anaïs
  • Domínguez-Alonso, Carmen
  • Neves, Maria
  • Morales, Pablo
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Guedan, Sonia|||0000-0002-9605-0760
  • Sanz, Laura
  • Toribio, Maria L.
  • Roda-Navarro, Pedro
  • Juan, Manel|||0000-0002-3064-1648
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Álvarez-Vallina, Luis
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies.